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A bstract
Noonan Syndrome (NS) is characterised by short stature, typical facial dysmorphology and 
congenital heart defects. The incidence of NS is estimated to be between I:I000 and 1:2500 live 
births. The main facial features of NS are hypertelorism with down-slanting palpebral fissures, 
ptosis and low-set posteriorly rotated ears with a thickened helix. The cardiovascular defects most 
commonly associated with this condition are pulmonary stenosis and hypertrophic 
cardiomyopathy. Other associated features are webbed neck, chest deformity, mild intellectual 
deficit, cryptorchidism, poor feeding in infancy, bleeding tendency and lymphatic dysplasias. The 
syndrome is transmitted as an autosomal dominant trait. In approximately 50% of cases, the disease 
is caused by missense mutations in the PTPNII gene on chromosome 12, resulting in a gain of 
function of the non-receptor protein tyrosine phosphatase SHP-2 protein. Recently, mutations in 
the KRAS gene have been identified in a small proportion of patients with NS. A  D N A  test for 
mutation analysis can be carried out on blood, chorionic villi and amniotic fluid samples. NS should 
be considered in all foetuses with polyhydramnion, pleural effusions, oedema and increased nuchal 
fluid with a normal karyotype. With special care and counselling, the majority of children with NS 
will grow up and function normally in the adult world. Management should address feeding 
problems in early childhood, evaluation of cardiac function and assessment of growth and motor 
development. Physiotherapy and/or speech therapy should be offered if indicated. A  complete eye 
examination and hearing evaluation should be performed during the first few years of schooling. 
Preoperative coagulation studies are indicated. Signs and symptoms lessen with age and most adults 
with NS do not require special medical care.
Disease name and synonyms
Noonan syndrome (NS)
(Mistakenly: male Turner syndrome, Turner phenotype 
with normal karyotype, female Turner-like syndrome)
Definition and diagnostic criteria
Noonan Syndrome (NS) is an autosomal dominant disor­
der characterised by short stature, typical face dysmor- 
phology and congenital heart defects. NS is a clinical
diagnosis. Establishing the diagnosis can be very difficult, 
especially in adulthood. There is a great variability in 
expression and the phenotype becomes less pronounced 
with increasing age [1]. Several scoring systems have been 
devised to help the diagnostic process. The most recent 
scoring system was developed in 1994 [2] (Table 1).
Epidem iology
The incidence of NS is reported to be between 1 in 1000 
and 1 in 2500 live births [3,4].
Page 1 of 6
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2007, 2:4 
Table 1: Scoring  system  for Noonan  syndrom e (N S )  #
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Feature A  =  M ajor B =  M in o r
1 Facial
2  Card iac
3 Height
4 C h e st  wall
5 Family h istory
6 O th e r
Typical face d ysm o rp h o lo gy
Pulm onary valve stenosis, H O C M  and/or E C G
typical o f N S
< P 3 *
Pectus carinatum/excavatum  
First degree relative w ith  definite N S  
Mental retardation, cryptorch id ism  and 
lymphatic dysplasia
Suggestive face d ysm o rp h o lo gy  
O th e r  defect
< P I0 *
B ro ad  tho rax
First degree relative w ith  suggestive N S  
O n e  o f mental retardation, cryptorch id ism , 
lymphatic dysplasia
H O C M :  hypertroph ic  obstructive  card iom yopathy;
*P 3  and P I0  refer to  percentile lines fo r height accord ing to  age, w ith  the norm al range o f variation  defined as P3-P97  inclusive 
Definitive N S: I "A "  plus one  o th e r m ajor sign o r  tw o  m ino r signs; I "B "  plus tw o  m ajor signs o r  th ree  m ino r signs
#  adapted from  [2]
C lin ical description
Common features of NS include:
Characteristic facial features that change with age
In the postnatal period the forehead is broad and high, 
there is hypertelorism, epicanthic folds and downward 
slanting palpebral fissures, low-set posteriorly rotated ears 
with a thick helix, high arched palate, micrognathia, and 
a short neck with excess nuchal skin and a low posterior 
hairline. The contour of the face becomes more triangular 
with age and in childhood the face often appears coarse or 
myopathic, with prominent eyes and (unilateral or bilat­
eral) ptosis, and thick lips with prominent nasolabial 
folds. In the adolescent and young adult, the eyes are less 
prominent and the neck appears less short. Sometimes 
there is marked webbing or prominent trapezius. Typi­
cally, older adults have prominent nasolabial folds, a high 
anterior hair line, thick hooded eyelids and wrinkled skin 
[1,4]. The facial features can be subtle, especially at old 
age.
The most common congenital heart defect is pulmonary 
valve stenosis with dysplastic leaflets (50%-62%) [5,6]. 
Hypertrophic obstructive cardiomyopathy (HOCM) with 
asymmetrical septum hypertrophy is present in 20% of 
patients. Atrial septal defects occur in 6%-10% of cases, 
ventricular septal defects occur in 5% of cases and persist­
ent ductus arteriosus occurs in 3% of cases [3,4]. Other 
congenital heart defects more often seen in NS are atriov­
entricular canal defect (AVCD) associated with subaortic 
obstruction and structural anomalies of the mitral valve
[7].
Electrocardiograms (ECG) from NS patients display wide 
QRS complexes with a predominantly negative pattern in 
the left precordial leads (62%). They also display left axis 
deviation and giant Q waves [5,8].
Weight and length are usually normal at birth. Birth 
weight can be high due to subcutaneous oedema. In such 
cases, marked weight loss occurs in the first week of life. 
Neonatal feeding difficulties and failure to thrive are 
present in 63% of patients [4]. In general, these feeding 
problems resolve spontaneously later in infancy. Mean 
prepubertal growth parallels the 3rd centile for height and 
weight. Onset of puberty is delayed by approximately two 
years and the pubertal growth spurt is often reduced or 
absent. The average bone age is also delayed by two years. 
Mean adult height is 162.5 cm in males and 152.7 cm in 
females. Both values are below the 3rd centile. Noonan- 
specific growth curves were designed in 1988 [9]. Growth 
hormone (GH) levels are in the normal range. Somatome­
din levels are elevated in some cases. GH treatment in 
pharmacological doses can be used to accelerate growth 
during the first years of life. Initial reports on the long­
term effects of this treatment show a beneficial effect 
[10,11]. NS patients with a mutation in the PTPN11 gene 
respond less efficiently to GH than NS patients without a 
mutation in PTPN11 [12].
Characteristic chest deformities consist of pectus carina­
tum superiorly and pectus excavatum inferiorly. These 
sternal abnormalities are present in 70%-95% of cases. 
The thorax is broad and the internipple distance is large. 
About 15% of patients develop thoracic scoliosis. The 
shoulders are often rounded with scapula alata. Other 
common orthopaedic features include cubitus valgus 
(50%), radioulnar synostosis (2%), clinobrachydactyly 
(30%), joint hyperextensibility (50%) and talipes equino- 
varus (12%) [3,4]. Giant cell lesions of the jaw, similar to 
those seen in cherubism, have been reported in several 
patients [13].
Undescended testicles at birth are common in male 
patients (77%). Increased luteinizing hormon (LH) and 
follicle stimulating hormone (FSH) levels are present in
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prepubertal boys [14]. High FSH levels and poor quality 
semen have been found in adults, suggesting a failure of 
spermatogenesis in patients with testicular maldescent
[15]. In both sexes, pubertal development is delayed. The 
mean age of menarche in female patients is 14.6 years [4]. 
However, fertility is not impaired in females with NS.
Urinary tract malformations are present in 10% of cases, 
mostly pyelo-ureteric stenosis and/or hydronephrosis 
[4,16].
Increased bruising or bleeding is frequent, especially in 
childhood. Up to 55% of cases have a mild-to-moderate 
bleeding tendency. Severe haemorrhage occurs in 3% of 
cases. Coagulation studies reveal prolonged bleeding 
times, factor VIII, XI and XII deficiencies, thrombocyto- 
paenia and platelet function defects. These manifestations 
appear individually or in combination [4,17]. For NS 
patients, there is no correlation between the results of 
coagulation tests and a history of easy bruising. Thus, 
these tests may not be predictive of bleeding risk in NS 
patients. Since many patients undergo one or more oper­
ations, special care is required to prevent intraoperative or 
postoperative haemorrhage. Suitable blood products 
should be made readily accessible in case such complica­
tions arise [18].
Acute leukaemia and myeloproliferative disorders
(MPD) have been described in some patients. The 
218C>T mutation in the PTPN11 gene is associated with a 
predisposition to an MPD, which most often resolve 
spontaneously [19]. In rare cases, individuals with NS can 
develop fatal MPD, typically juvenile myelomonocytic 
leukaemia (JMML). However, the prognosis for NS 
patients with JMML is better than that for non-NS patients 
with JMML [19,20].
Lymphatic vessel dysplasia, hypoplasia, or aplasia are
common findings in NS (20%). They lead to generalised 
lymphoedema, peripheral lymphoedema, pulmonary 
lymphangiectasia or intestinal lymphangiectasia. The 
most common manifestation is dorsal limb lym- 
phoedema, which usually disappears during childhood. 
Varying degrees of oedema or hydrops are present during 
intrauterine life. Ultrasound examination may reveal a 
cystic hygroma in early pregnancy. This swelling subse­
quently regresses and results in excess nuchal skin and 
pterygium colli after birth. Other features, which may be 
due to disruption of normal tissue migration or organ 
placement by foetal oedema, are cryptorchidism, wide­
spaced nipples, low-set posteriorly rotated ears, hyperte­
lorism and downward slanting palpebral fissures [21,22]. 
Spontaneous chylothorax may occur in childhood and 
chylous effusion is a known complication of cardiac sur­
gery and surgery for thoracic deformity [23,24].
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Abnormalities of pigmentation in NS include pigmented 
naevi (25%), cafe-au-lait spots (10%) and lentigines (3%). 
Ulerythema ophryogenes (keratosis pilaris atrophicans 
faciei) is present in 14% of cases and may lead to a lack of 
eyebrows. NS is also often accompanied by keratosis pila­
ris on the upper arms [4,25]. Approximately one-third of 
the patients have thick curly hair, and 10% have thin 
sparse hair. Foetal pads on fingers and toes are common 
(67%) [4].
Frequent ophthalmic abnormalities are strabismus 
(48%-63%), refractive errors (61%) and amblyopia 
(33%). Anterior segment changes (63%) and fundal 
abnormalities (20%) may be present, nystagmus is seen in 
10% of NS patients [26,27].
Hearing loss due to otitis media is a frequent complica­
tion (15%-40%). Sensorineural hearing loss is less com­
mon, but involves the low frequency range in 10% of 
patients and the high frequency range in 25% of patients 
[28]. Structural anomalies of the inner ear have occasion­
ally been reported [29,30] and vestibular abnormalities 
have been described in a single case [31].
Hepatosplenomegaly unrelated to cardiac failure is often 
present in infancy (26%-51%). It is less frequent with 
higher age. There are no reports of hepatic and/or splenal 
dysfunctions being associated with the organomegaly 
[4,19].
In general, children with NS demonstrate mild motor 
delay, which may be partly attributed to the muscular 
hypotony that is often present in early childhood. Mean 
age for sitting is 10 months, that for walking alone is 21 
months, and that for talking is 31 months [4]. Articula­
tion abnormalities are frequent (72%). Mental retarda­
tion is present in 15%-35% of cases and is usually mild. 
It is characterised by specific visual-constructional prob­
lems and verbal performance discrepancy. Mean full scale 
intelligence quotient (IQ) is 85, but there is a wide range 
in the level of intelligence [32,33]. Prominent behavioural 
problems are clumsiness, eating problems, fidgety or stub­
born spells, echolalia and irritability. Social problems and 
attention deficit have also been noted. In spite of this wide 
range of reported behavioural problems, most authors 
state that children with NS can be raised with parental 
support alone, without any specialised intervention [34].
Aetiology
NS may occur on a sporadic basis or in a pattern consist­
ent with autosomal dominant inheritance with a predom­
inance of maternal transmission.
In approximately 50% of the patients with definite NS, a 
missense mutation is found in the PTPN11 gene on chro­
mosome 12. PTPN11 encodes the non-receptor protein 
tyrosine phosphatase SHP-2. This enzyme is involved in a
http://www.OJRD.com/content/2/1/4
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wide variety of intracellular signal cascades downstream 
of receptors for growth factors, cytokines and hormones, 
and is required in several developmental processes [35]. 
The mutations associated with NS result in a gain of func­
tion of SHP-2 [36].
Heterogeneous gain-of-function mutations in PTPN11 are 
found in almost half of the patients with clinically definite 
NS. These mutations are found in 59% of the familial 
cases and in 37% of the sporadic cases. Most of the muta­
tions are recurrent and cluster in exons 3, 8 and 13. 
Among individuals with NS, those with a mutation in 
PTPN11 more often have pulmonary valve stenosis, while 
those without a mutation in PTPN11 more often have a 
cardiomyopathy The most frequent NS-causing PTPN11 
mutation is an A-to-G transition at nucleotide 922. This 
transition accounts for 25% of all NS-causing PTPN11 
mutations and leads to a Asn308Asp substitution. This 
mutation is often found in familial cases and is not asso­
ciated with any developmental abnormality. A genotype- 
phenotype correlation has also been identified between a 
C-to-T transition on nucleotide 218 (Thr73Ile) and a pre­
disposition to a myeloproliferative disorder. This disorder 
most often resolves spontaneously [19,20,36]. Recently 
activating mutations in the KRAS gene, which is associ­
ated with the Ras pathway, were found as the causative 
dominant mutations in a few cases with NS. These find­
ings establish hyperactive Ras as a cause of developmental 
abnormalities seen in NS [37].
Diagnostic methods
Noonan syndrome is a heterogeneous but clinically recog­
nisable, multiple congenital anomaly syndrome. Scoring 
systems can help the diagnostic process [2]. NS mostly 
occurs on a sporadic basis or in a pattern consistent with 
autosomal dominant inheritance, with a predominance 
of maternal transmission [3,4,19,20]. The de novo PTPN11 
mutation in sporadic NS cases is predominantly of pater­
nal origin [38]. However, there is evidence for a rare auto­
somal recessive form of NS [39].
Differential diagnosis
There are a number of conditions with phenotypes strik­
ingly similar to NS. The first to mention is Turner syn­
drome (45, X0), a well known chromosomal abnormality 
in girls. Then there are a group of distinct syndromes with 
partially overlapping phenotypes in which causative 
mutations are found in genes of the RAS-MAPK pathway. 
These include Cardio-Facio-Cutaneous (CFC) syndrome, 
Costello syndrome, Neurofibromatosis type 1 (NF1) and 
LEOPARD syndrome (multiple lentigines, ECG conduc­
tion abnormalities, ocular hypertelorism, pulmonic sten­
osis, abnormal genitalia, retardation of growth and 
deafness). Individuals with LEOPARD syndrome may 
have distinct mutations in PTPN11 wich lead to a dimin­
ished catalytic activity of these SHP-2 mutants. Costello 
syndrome is caused by mutations in HRAS, NF1 by muta­
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tions in Neurofibromin and CFC syndrome by mutations 
in BRAF, KRAS and MEK1/2 [40,41].
Syndromes that are characterised by facial dysmorphol- 
ogy, short stature and cardiac defects may sometimes be 
difficult to differentiate from NS, notably Williams syn­
drome and Aarskog syndrome [42].
G enetic counselling
Before the child is born, consultations with parents may 
address the following, as appropriate:
* Explain the mechanisms for occurrence or recurrence of 
NS in the foetus and the recurrence risk in the family.
* Review the natural history and manifestations of NS, 
including variability.
* Discuss further studies that should be done, particularly 
those in the newborn period that will confirm the diagno­
sis. If miscarriage, stillbirth or termination occurs, confir­
mation of the clinical diagnosis by autopsy is also 
important.
* Review the currently available treatments and interven­
tions.
* Explore the options available to the family for the man­
agement and rearing of the child.
Antenatal diagnosis
NS should be considered in all foetuses with polyhydram­
nion, pleural effusions, oedema and increased nuchal 
fluid with a normal karyotype [21,43]. If there is clinical 
evidence of NS in the foetus or a first-degree relative has 
NS, obstetric ultrasound is indicated at 12-14 and 20 
weeks' gestation and again in the third trimester. Foetal 
echocardiography is indicated at 18-20 weeks' gestation. 
If NS is suspected in the unborn child, physical examina­
tion of the parents for features of the syndrome is indi­
cated. As normalisation of the facial phenotype with age 
is common in NS, a review of childhood photographs of 
both parents is often helpful. A DNA test for mutation 
analysis can be carried out on blood, chorionic villi and 
amniotic fluid samples. Herewith also preimplantation 
genetic diagnosis becomes a possibility.
M anagem ent including treatm ent
The majority of children with NS will grow up and func­
tion normally in the adult world. However, they need spe­
cial care and counselling. Below is a set of guidelines 
designed to assist physicians caring for NS patients and 
their families. Familiarity with the characteristic features 
of NS is clearly important for clinical geneticists, cardiolo­
gists, surgeons, anaesthetists, gynaecologists, paediatri­
cians and dermatologists. Issues that need to be addressed 
at a given age are discussed.
http://www.OJRD.com/content/2/1/4
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Issues that need to be addressed
From birth to I month -  newborns
* Confirm diagnosis.
* Extensive cardiological examination including echocar­
diography.
* Appropriate laboratory studies, including chromosome 
analysis and DNA analysis (PTPN11, KRAS) if possible.
* Document measurements.
* Hepatosplenomegaly?
* Undescended testes in male patients? Initiate treatment 
if present.
* Weight loss in the first week.
* Hypotonia, poor feeding and failure to thrive.
* Offer extensive genetic counselling to the parents.
From I month to I year -  infancy
* Growth and development.
* Serous otitis media.
* Cardiologic evaluation.
* Feeding and feeding difficulties.
* Support available to the family.
* Motor development (expect mild motor delay in most, 
but significant psychomotor delay in only a minority of 
patients).
From I to 5  years -  early childhood
* Growth and development.
* Cardiologic evaluation.
* Speech.
* Easy bruising/coagulation.
* Cutaneous findings.
* Partial growth hormone deficiency?
* Possibility of growth hormone therapy in very small NS 
children with partial growth hormone deficiency.
* Behaviour and possible behavioural problems.
From 5  to I3  years -  late childhood
* Social adaptation.
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* Skeletal age.
* Growth hormone therapy if indicated.
* Cardiologic evaluation.
* School readiness/intellectual capabilities.
* Vision and hearing.
* Delay in puberty (on average about 2 years).
* Contact with other patients (especially valuable at this 
age)
* School performance.
From I3  to 2 I  years or older -  adolescence to early adulthood
* Auxological parameters.
* Cardiologic evaluation.
* Coagulation (bleeding abnormalities present in child­
hood often resolve with age).
* Growth hormone therapy (if indicated) until adult 
height is reached.
* School performance and choice of profession.
* Genetic counselling at adolescent or young adult age. 
Prognosis
New medical problems are not expected to appear in 
adulthood. However, males who were born with unde­
scended testes may have fertility problems. There is no evi­
dence for gynaecological or childbearing complications in 
females with NS. Some patients have health problems as 
a consequence of their congenital heart defect, lymphatic 
vessel dysplasia, urinary tract malformation, haematolog­
ical disorder, or other anomaly associated with NS. None­
theless, most adults with NS do not require special 
medical care.
U nresolved questions
It is clear that there is wide variability in the phenotypic 
expression of NS and that there are many unresolved 
questions. The phenotype varies from adults with mild 
facial features and a minimal pulmonary valve stenosis to 
severe dysmorphisms plus life-threatening heart disease 
in neonates. Furthermore, there is a wide variability in the 
intellectual and adaptive behaviour. It is not clear from 
where this wide variability in symptoms stems. Genotype- 
phenotype correlation studies among individuals with NS 
caused by a mutation in PTPN11 give some insights. The 
finding of mutations in one of the key genes in the RAS 
pathway (KRAS) in some patients with NS, however, rises 
a lot of new questions. There are overlapping features with
http://www.OJRD.com/content/2/1/4
Page 5 of 6
(page number not for citation purposes)
Orphanet Journal o f Rare Diseases 2007, 2:4 http://www.OJRD.com/content/2/1/4
Costello and CFC syndrome in NS, but there are also very 
different features present in these clinically distinct syn­
dromes. The finding of germline gain-of-function muta­
tions in genes from the RAS-MAPK pathway in NS, 
Costello and CFC syndrome unexpectedly assigns roles in 
human development to genes, which are much better 
known for their effects on dysregulation of cell signalling 
in cancer cells.
The aetiology of NS in individuals without mutations in 
PTPN11 or KRAS (almost 50% of cases) is still unknown. 
Research aimed at identifying the other gene(s) responsi­
ble for NS is ongoing.
Other unexplained findings of interest are: the near 
absence of large families with NS, the fact that all cohorts 
in studies of NS included more male than female patients, 
and why results of coagulation tests are not predictive of 
the bleeding risk in people with NS.
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